EUVIMEDEUVIMED entdecken
FallberichtOpen Access · CC BY 4.0

Severe Myositis, Myocarditis, and Myasthenia Gravis with Elevated Anti-Striated Muscle Antibody following Single Dose of Ipilimumab-Nivolumab Therapy in a Patient with Metastatic Melanoma

Mahdieh Fazel iD, Patrick M Jedlowski iD

Case Reports in Immunology · 30.04.2019 · 2019 · 1-3

DOI: 10.1155/2019/2539493 ↗

Kurz gefasst

Fallbericht in der Zeitschrift Case Reports in Immunology, erschienen am 30.04.2019. Verfasst von Mahdieh Fazel und 1 weiteren Autor:innen. Beteiligte Einrichtung: University of Arizona College of Medicine - Tucson, 1501 N Campbell Ave, Tucson, AZ 85724, USA. Die Arbeit wurde bisher 46-mal zitiert (Crossref) und nennt 10 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Immune checkpoint inhibitors targeting programmed cell death protein 1 and cytotoxic T-lymphocyte associated protein 4 have improved survival in patients with metastatic melanoma, especially in combination (i.e., ipilimumab-nivolumab). Postmarketing surveillance has identified rare but at times life-threatening adverse effects associated with these agents in combination and as monotherapy, which include myocarditis, myositis, myasthenia gravis (MG), and hepatotoxicity. Further evaluation of immune checkpoint therapy-induced MG identified the rapid clinical progression, prolonged treatment/supportive therapy course, and higher frequency of myasthenic crisis in these patients versus those with idiopathic MG. More rapid incorporation of aggressive treatment options (i.e., intravenous immunoglobulin, plasmapheresis) may be necessary in these cases. Anti-striational antibodies are often detected in individuals with myasthenia gravis and concurrent myositis and myocarditis. A high-index of suspicion is necessary to assist with rapid treatment initiation as these patients can rapidly deteriorate into respiratory compromise. A case of a 78-year-old woman with metastatic melanoma status after combination therapy with ipilimumab-nivolumab that developed transaminitis, myositis, myocarditis, and myasthenia gravis (with positive anti-striational antibodies) five days after the first cycle, is presented. Despite high dose intravenous methylprednisolone and intravenous immunoglobulin treatment, she ultimately entered hospice care eight days after hospital admission, 36 days after her first cycle.

Autor:innen und Institutionen

  • University of Arizona College of Medicine - Tucson, 1501 N Campbell Ave, Tucson, AZ 85724, USA.

ORCID-Profile: Mahdieh Fazel, Patrick M Jedlowski

Zitieren

APA

Fazel, M., & Jedlowski, P. M. (2019). Severe Myositis, Myocarditis, and Myasthenia Gravis with Elevated Anti-Striated Muscle Antibody following Single Dose of Ipilimumab-Nivolumab Therapy in a Patient with Metastatic Melanoma. Case Reports in Immunology, 2019, 1-3. https://doi.org/10.1155/2019/2539493

Vancouver

Fazel M, Jedlowski PM. Severe Myositis, Myocarditis, and Myasthenia Gravis with Elevated Anti-Striated Muscle Antibody following Single Dose of Ipilimumab-Nivolumab Therapy in a Patient with Metastatic Melanoma. Case Reports in Immunology. 2019;2019:1-3. doi:10.1155/2019/2539493

BibTeX
@article{Fazel2019,
  author = {Fazel, Mahdieh and Jedlowski, Patrick M},
  title = {Severe Myositis, Myocarditis, and Myasthenia Gravis with Elevated Anti-Striated Muscle Antibody following Single Dose of Ipilimumab-Nivolumab Therapy in a Patient with Metastatic Melanoma},
  journal = {Case Reports in Immunology},
  year = {2019},
  volume = {2019},
  pages = {1--3},
  doi = {10.1155/2019/2539493}
}
Kostenlos starten →